PeerView Internal Medicine CME/CNE/CPE Audio Podcast PeerView

Go online to PeerView.com/WCP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options. Upon completion of this activity, participants should be better able to: Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis; Identify patients with psoriasis who are most likely to benefit from novel oral treatments; Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines; and Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis.

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding patient access to CAR-T therapy. Expert panelists discuss the key data supporting CAR-T therapy in hematologic cancers and provide guidance on principles of outpatient cellular therapy, lessons derived from the outpatient experience with stem cell transplantation, and strategies to overcome barriers to patient selection, adverse events, and adequate staffing. Upon completion of this activity, participants should be better able to: Summarize current evidence supporting the integration of CAR-T constructs into the management of hematologic cancers, including in earlier and later lines of care; Cite the infrastructure and design for an outpatient cellular therapy program and the relevant practical experience from home-based transplantation initiatives; Develop strategies for optimal patient selection, staffing, and management of adverse events in the context of an outpatient cellular therapy program; and Employ tools such as quality metrics, telemedicine, and wearable devices in an outpatient cellular therapy program to ensure successful delivery of CAR-T therapy

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that exist with the integration of recently approved and emerging targeted therapies into the modern care of patients with NSCLC. Better grasp the oncogenic role of different genomic alterations and the associated biomarker tests for capturing them to enable the most appropriate selection of targeted therapies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC; Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC; and Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials

Go online to PeerView.com/FSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. After many years of slow progress, the treatment arsenal has finally expanded and more hope is on the horizon for patients with small cell lung cancer (SCLC). Notable advances such as chemo-immunotherapy in the first-line setting and lurbinectedin in the second-line setting have now become guideline-recommended standards of care and propelled the treatment of SCLC forward. Further research efforts are focused on understanding the underlying biology and potential subtypes of SCLC, what biomarkers may be useful in refining treatment selection, and evaluation of novel therapeutic options and rational combinations. In this PeerView Live Candid Conversations & Clinical Consults symposium, based on a recent live symposium, leading experts weave together the latest evidence on standard-of-care therapies and the evolving data on new/emerging approaches to provide a big-picture overview of the present and future management of SCLC and how to accelerate further progress in this challenging disease. These discussions are framed with illustrative patient cases to highlight evidence-based strategies to improve care and outcomes in SCLC. Upon completion of this activity, participants should be better able to: Analyze the role and use of current and emerging therapies for SCLC and the evidence supporting their use; Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, rapid initiation of therapy, and optimal care throughout the disease continuum for each patient with SCLC; Incorporate current standard-of-care therapies into individualized treatment plans for eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC to facilitate progress and improve outcomes